Vaping Affiliate Programs Guide and Reviews - How To

Tasty Vapor Premium E-Liquids Affiliate Program

We just launched the Tasty Vapor Affiliate Program and you can see it here -> http://Affiliate.TastyVapor.us
Earn 13% commission on sales.
submitted by TastyVaporMixTeam to Affiliatemarketing [link] [comments]

2020 Psychedelic Industry Insights Report

By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best Decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Due to poor understanding of mechanisms, complex clinical trials and systematic side effects, Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to reduce or cut their Neuro programs in the last decades. Recently, engagement is exploding with new clinical legislature supporting Neuro and the recent approval of 3 potentially blockbuster Neuro drugs in the last 2 years,
Q2 2019 saw a record of over $320M in investment into Neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals including PayPal founder Peter Thiel funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. In 2019 Atai Lifesciences acquired Perception Neuroscience and GABA Therapeutics for their next generation tranquillisers. Last week, Atai also acquired NeuroNasal, a non-psychedelic company creating a concussion nasal spray. In partnership with pharma, Atai's recent launch of EntheogeniX, an AI based psychedelic drug discovery platform, shows that Atai is serious about making investments into the fundamental research required to continue being an industry leader in the long-term. It is rumoured that Atai has made a number of cash investments recently, so new partnerships and acquisitions should be expected in the next months.
The collapse of investable cannabis opportunities are driving investors comfortable in stigmatised industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelics Industry?
Historically, the psychedelics industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $220M+ worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-25 early companies in the range of $2.5-10M each. The $220M+ worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelics Market?
The psychedelics market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B+
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight:
Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $100M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, $15M+, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $12M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh Pharmaceuticals - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen Labs - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $8M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020
Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $35M+ in emerging deals in Q3 2019 which have not passed due diligence.
Clinical:
Recent data is showing psychedelics can be real mega blockbuster Neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. This is showing addiction can be treated with new mechanisms that are much more low level than replacing the drug in the receptor. Academic data unequivocally shows that Ibogaine is 95% successful in terminating acute opioid withdrawal symptoms permanently from a single dosage. Limited data from long-term Ibogaine for opioid addiction trials show 50% success rates in terminating addiction in the 6 month period with a single dosage, more than 10X higher than the generous 5% success rate of other approaches in the 6 month period. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched crack again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards. Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B+ in value yearly. Ibogaine's very reasonable projected 5% penetration into the opioid dependence market in the next 10 years will bring $9.6B+ in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialisation of the current late stage clinical trials which are in progress.
Highlight:
Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved for the general market. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drug Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location. Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next few years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of Ibogaine to endangered status in 2019 and no synthetic GMP producers - the Ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk. At the current moment, around 5-10 psychedelic investment funds are forming in the range of $10-50M each, including the Cannacord Genuity backed Entheos and the $20M psychedelic quant fund Tabula Rasa Ventures.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8+ trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $0.75 through automation, mushroom protein becomes significantly more commercially competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective and produces a life threatening condition called Precipitated Withdrawal. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200X microdoses. When dosages increase past the perceptual threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development:
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for neural growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptor system. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh Pharmaceuticals, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic, fueled secondarily by histories cheapest and most available synthetic drugs. With Johnson and Johnson settling with two counties in Ohio, projections have placed the total at $100B+ in fines for the opioid crisis in the next few years. State jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterised by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
submitted by mindovermatterlondon to investing [link] [comments]

2020 Psychedelic Industry Insights Report - ThinkMyco

2020 Psychedelic Industry Insights Report
By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
[email protected]
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to liquidate their neuro programs in the last decade. Recently, engagement is exploding with new clinical legislature supporting neuro, the recent approval of 3 potentially blockbuster neuro drugs in the last 2 years, Q2 2019 saw a record of over $320M in investment into neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals to funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. The collapse of investable cannabis opportunities are driving investors comfortable in stigmatized industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelic Industry?
Historically, the psychedelic industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $300M worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-15 early companies in the range of $2.5-10M each. The $300M worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelic Market?
The psychedelic market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight: Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $150M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, raising $15M, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $10M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $5M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020 Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $25M+ in emerging deals in Q3 2019 which have not passed due diligence.

Clinical:
Recent data is showing psychedelics can be real mega blockbuster neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. Academic data shows that Ibogaine is 95% successful in terminating acute opioid withdrawal/addiction. Limited data from Ibogaine for opioid addiction trials show 50% success rates in terminating addiction, more than 10X higher than the generous 5% success rate of other approaches. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched cocaine again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards, Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B in value. Ibogaines very reasonable projected 4% penetration into the opioid dependence market will bring $9.6B in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialization of current late stage clinical trials.
Highlight: Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drugs Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location.
Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next two years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of ibogaine to endangered status in 2019 and no synthetic GMP producers - the ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.
A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8 trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $1.20 through automation, mushroom protein becomes significantly more competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200x microdoses. When dosages increase past the perception threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development:
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptors. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic fueled secondarily by histories cheapest and most available synthetic drugs. With $100B+ in fines projected for the opioid crisis in the next few years, state jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterized by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
Additional information requests: [[email protected]](mailto:[email protected])
submitted by mindovermatterlondon to shroomstocks [link] [comments]

Supervillainy and Other Poor Career Choices - Chapter Thirty Nine

It was well after one in the morning when Ethan staggered into his apartment. Blearily resetting the lock on the door, he stepped into the kitchen, careful not to make too much noise as he slipped off his Saints jacket and placed his gun down on the kitchen table.
Normally the weapon was locked away in his room within moments of him entering the house, but the man figured that given the hour, the weapon was safe from questing hands for just the moment.
At least, it damn well better be, he thought wryly. It was a school night after all, and if the kids weren’t in bed and fast asleep by now there was going to be hell to pay.
A quick peak upstairs filled him with relief though. Both his kids were there, snoring away in their rooms.
The sight soothed him.
As it always did.
As much as he wanted to make the journey across the hall to his own bed to finally rest his weary body, he knew from long experience that even if he did, no sleep would be forthcoming. He would just lie there, awake and jittery.
He always was after a firefight, and he knew it would take hours before he was calm enough to even attempt to go to sleep.
Of course, by the time that happened he would need to get back up again anyway to get the kids ready for school, make breakfast, and pack them both a lunch each. They could do it themselves of course, Brock and Shelly were certainly old enough now, but it was the one time of the day he actually got to see them and he refused to give it up.
His kids might not have a mother anymore, but he would be damned if they didn’t have a dad.
Of course, that still left him with a few hours to burn.
Considering the wafer-thin nature of the buildings cheap walls, watching tv was right out. The house had come with a few books on the shelves, but no one in the family was much of a reader, and they had very quickly found themselves pawned off.
Which really just left him with one option.
The laptop.
Pulling the old computer out of its hiding place, Ethan winced as the clattery old thing’s fans loudly whirred to life, disturbing the quiet of his home. Still, slow, noisy and laborious as the ancient machine’s boot-up was, it did eventually start up properly.
Firing up the web-browser, the father of two momentarily considered going straight to a porn site.
Firing one off was one way he’d found to ‘relieve’ tension after a particularly close call – and the today’s brief shootout with the Kings certainly counted. The purple cunts had been getting more and more brazen about pushing up against Saints territory, and today had finally been the day that something had popped off.
He’d been lounging around with a few other guys, ostensibly guarding the lobby of a Saint ‘sponsored’ whorehouse, when a dozen purple cunts had charged in and started shooting up the place. It was pure luck that Ethan wasn’t one of the guys caught up that initial salvo, and he’d hastily scrambled past the screaming whores – and Saints – to dive over the bar.
Which of course, being in Portland, was reinforced enough to act as decent cover from a hail of gunfire.
Not that that knowledge had given him much relief, as gunfire rang out, and shattered bottles of booze fell all around him.
His clothes, while no longer soaked as a result of that experience, still stunk like a brewery.
Which at the very least, is still a step-up from blood, he shuddered, remembering the scene that greeted him when the gunfire had stopped and he’d dared to peak his head out.
Now Ethan was no bleeding heart. He used whores, and he wasn’t delicate about it. That’s what they were paid for, just like he was paid to crack heads, and possibly have his own cracked in turn.
That was life.
But even he’d felt his stomach turn at what remained of the front of that bordello. Men and women in various states of undress, strewn about and bleeding. Some dead. Some alive and screaming.
He could still remember looking out at a young woman, scarcely a few years older than Shelly, slumped over a couch, eyes wide and glassy as they stared off into nothingness.
Of course, that had been the moment the surviving Saints returned fire, and he’d been forced to remember that he had a job to do. Everything thereafter had devolved into a continuous haze of panic and anger.
What felt like hours of it.
Stuck in a stalemate.
And then it ended just suddenly as it had begun.
Out of nowhere, a big purple bitch had run straight into the Kings, shrugging off gunfire without batting an eyelash.
It was all over after that, Zigzag had showed up while the Amazonian woman was mopping up, he’d been debriefed on what happened, given his ‘hazard pay’ and sent on his way home.
Still, that image stuck in his mind. That purple bruiser shrugging off bullets like they were nothing.
Less than nothing.
The Kings couldn’t harm her with what they had on hand, and she knew it.
“Prowler,” he murmured, finally remembering the name of the Bruiser. The chick who’d shown up a few months back.
“Didn’t she also bring in a few more meta-human’s recently?” A lightning chick for sure, he’d definitely seen that one about. A snooty blonde with a freaky mask. Her and two others. He vaguely recalled someone talking about a chick who make stuff float a few days back…
Which just left the last one. It was a dude, which was rare, so it should have stuck out in his mind.
He was an Artificer wasn’t he?
He was sure he was, but he also swore he heard someone saying he wasn’t. Then he remembered something.
Guns.
He’d seen a few guys wondering around with some fancy looking hardware just last week. He’d had no idea what the massive rifles did, but based on all the dials and wires on the things, he was willing to bet it was something fancier than spit lead.
Some kind of blackhole cannon or some shit like that.
He was willing to be that a gun like that would give even a Bruiser pause for thought.
Idly he ran a hand hand over where his own gun sat. A cheap Chinese knockoff of the classic BP-5, the thing was popular on the coast for its reliability and ease of maintenance. The thing didn’t have much stopping power or a great fire-rate, but it was light and had next to no recoil. Which made it an ideal weapon for women and children. Which also made it a perfect fit for somewhere like the West Coast, where the word civilian didn’t really exist. Everyone was a potential enemy combatant, and often employed as such.
Still, he thought looking over the bullpup, it might as well be a water gun for all the good it would do me if I went up against a meta…
That didn’t sit well with him. Not at all.
Coming to a decision, he typed in the address of the Saint’s forums.
The message board was pretty much an open secret amongst the gang, and he imagined other crews had something similar. The thing didn’t have any ‘official’ orders on it, but it was a convenient way for the gang to keep in touch and be kept up to date. The thing had some decent cyber security he didn’t quite understand, but Ethan knew Zigzag would come down like a sack of bricks on anyone who was dumb enough to think that meant it was safe to use to discuss any ongoing operations.
No, the place was more for the rank and file to be kept appraised of things going on. This could mean anything from rival gang movements to info on enemy Metas all the way down to which vendors were now ‘gang’ affiliated, and thus safe to buy from.
Which was exactly what Ethan was interested in.


Topic: Erich’s Armaments (Not Gravity’s Guns, as was previously posted.)
In: Associated Vendors
Bronte (Original Poster) (Member) (Meta) (Block Captain)Posted On July 6th 2019:Greeting Saints.
As I’m sure many of you already know, I am Bronte. What many of you do not know however is that I am a close associate of Mechromancer (the proprietor of Erich’s Armaments). As the man himself has declined to make himself or his business known on this message board, I have taken it upon myself to do it for him.
If you wish to speak to the man himself about his wares, you may do so at the store, although I would strongly recommend against it. The man has little patience for people, and I need not remind anyone of what happened to the last person to irritate him. For anyone who’s memory is faulty however, I would direct them to the street outside the store, where bits of Alloy might still be seen.
In the coming weeks I shall be classifying the myriad Meta-tech tools and weapons he has created before posting them on this site for your perusal. With that in mind, here is the first weapon he has begun the process of standardizing for sale:
The M2P3 ‘Red-Eye’ Laser Pistol:The Red-Eye functions as a fully automatic pistol in that so long as the trigger is depressed it will continuously pulse high power laser beams. These beams are more than capable of penetrating the body of a civilian car (TESTED), concrete (Tested), and the resistances of some low-level Bruisers (Tested). Upon coming into contact with the human body the beam flash-heats any water within, resulting in an effect known as ‘explosive vaporization’. In the event of a hit to an individual’s centre mass this effect is invariably instantly fatal.

BleedsWhiteandYellow (Member)
Replied on July 6th 2019:
The lady’s not lying. Bought one of these on a whim(an expensive one) a while back to use as a holdout weapon. Figured it looked intimidating if nothing else. Was forced to use it the other day and boy did it work. No recoil, but it’ll blow a hole in someone the size of a watermelon. In armour or behind cover? Doesn’t matter.

StreetMook (Member)
Replied on July 7th 2019:
Yeah, that’s good and all, but would it have killed you to mention it only has twenty shots? I nearly lost an eye today because it ran out an inopportune moment.

BeaverFur (Member) (Meta) (Unit Leader)
Replied on July 7th 2019:
StreetMook: That’s your own dumbass fault for not asking. What kind of idiot gets into a firefight without knowing how many shots is in his or her gun?

Old_Man (Member)
Probably one of the new guys Zigzag let in. I know we need bodies if we’re going to have a chance against the Kings, but some of these dumbasses…


Ethan sighed as the posts from there devolved into an argument between the new guys and the veterans. Ethan himself was a member of the latter group, but he personally had no issue with the new guys. As far as he was concerned every person they could put in white and yellow was another body between the Kings and his kids.
Still, this ‘Red-eye’ sounded exactly like what he was looking for.
Well, not exactly, he thought as he looked at the accompanying image. He wasn’t much a fan of pistols, least of all using them as a primary weapon. Lots of the kids in the outfit preferred them for ease of use and access, but Ethan knew that nine times out of ten they couldn’t hit the broad side of a barn door with one when bullets started flying. No, if you were using a pistol effectively then you were already closer to the fight than he wanted to be.
“And I’m damn well using it as my primary if I’m paying that much for it,” he muttered as he looked at the accompanying price tag.
Scrolling to the bottom of the page, he was relieved to see that the thread continued.


(Showing page 6 of 7)
CopKiller69 (Member)
Replied on July 16th 2019:
Got a King in the stomach with one today. Should have heard him scream like a piggy. Was downright magical to watch him try to scoop his guts back in.
Best. Gun. Ever.

HumanBeing (Member) (Unit Leader)
Replied on July 16th 2019:
CopKiller69: Let me guess, former Blood Hounds member? Seems we’re taking in anyone these days.
Finish him off quickly next time. The Saints at least like to pretend we’re better than the average thug.

Sebas_Tian (Member)
Posted On July 17th 2019:
Bronte: Do you know when Mechromancer’s gonna get more Red-Eye’s in? Girl at the desk said she didn’t know, and they’ve been sold out the last two times I’ve been in. Really need to get one. Manacle’s been sighted a few times round my block.

Bronte (Original Poster) (Member) (Meta) (Block Captain)
Posted On July 18th 2019:
Sebas_Tian: Erich should be restocking the Red-Eye in conjunction with his release of his latest products.
The M2S3-X1 ‘Hot-Shot’ Carbine:
Based on the frame of the M2S3, the Hot-Shot Carbine functions as a longer-range alternative to the classic Red-Eye. In addition the added stock, barrel length and coolant sheathe, the Hot-Shot has a heavy-duty powerpack slung under the barrel. This allows for a weapon with greater ammo capacity and firing speed than its predecessor, albeit at the cost of size and weight.
The MXD2 ‘Helot’ Sentry Drone
An entry level sentry drone, the Helot provides around the clock automated security to the customer on a budget. While neither particularly durable or adaptable, the Helot has the same basic programming suite as any other drone that may be found on the market. It is capable of utilizing firearms, patrolling in a set pattern, following an individual, and performing basic threat recognition.
Note: Firearm not included.

BeaverFur (Member) (Meta) (Unit Leader)
Replied on July 18th 2019:
The product description pretty much says it all. The Hot-Shot’s a beefier version of the Red-Eye. It’s got an ammo capacity of one hundred rounds rather than twenty, can fire for longer before overheating, and the stock reduces what little recoil was already there. The only downside is that it’s heavier, and you can’t conceal it. If you’re walking around with this thing, everyone’s going to know it. Whether that’s a positive or a negative is up to you.
As for the drone, I’ve got no idea. Saw a few in the shop while I was there. They look nothing like the one that sits behind the counter. Think the girl called it ‘Limpy?’ Weird fucking name for a drone. Thing doesn’t even limp.
The Helots on the other hand look like they’re held together by scrap and duct tape. Make no mistake, these things aren’t going to survive more than a few rounds before falling apart, if that. Still, they tracked me as I walked in, walked around, and they were holding their guns without falling over. So I suppose if you desperately need a drone for dirt cheap, you could do worse.
Not really much of a drone guy though, so I could be wrong.

TechnoFangirl (Member) (Block Leader)
Replied on July 19th 2019:
Beaver’s not wrong. I bought one to run a few tests. Ran it through a little obstacle course, before shooting a few targets. It passed.
If only barely.
Now this might not seem too impressive, until you consider the price of the things. A ‘proper’ sentry drone will cost the same as a decent car (bought not stolen), so these things are basically a bargain.
If I didn’t already have a dozen Omni-Tech drones already I would be filling out my ranks with these. As it is I’m recommending anyone in my block get one. They’re an extra set of hands (and a gun) in a fight, if nothing else.
Edit: And yes, one of the ones I picked up was using a reversed Omni-Pad as its primary visual system. When I say these things are cheap, I do mean cheap.
Edit: Edit: Strangest thing, I’ve pulled mine apart, and I still can’t find the Meta-Tech component. If anyone’s having better luck please PM me.


Ethan lost interest after that. The rest of the comments pretty much said the same thing.
“Hot-Shot, huh…” he murmured, glancing over at the attached price tag. The number made him suck air through his teeth.
It wasn’t a small amount. Not even close.
But is it worth more than your life? Came unbidden to him. Of their own accord, his eyes flicked upstairs.
No, no it wasn’t.
Saving the address of the shop to his phone, he made a mental note to head straight there after the kids left for school. His Block Leader would be pissed that he was late for his patrol, but he figured it would be worth it if it reduced the risk of the store selling out before he arrived.
Even a quick glance through the rest of the comments told him how popular these guns were getting, and he knew it was only a matter of time before demand outgrew supply.
It always did where Artificers were concerned.
Might even pick up one of those drones while I’m at it, he thought.
Who knew when a chance like this would come again? The guy could only make so many.
It wasn’t like the things were built on an assembly line.

As ever, despite my best efforts, a few errors always seem to slip through. If you see one, don't hesitate to point it out. I'll fix it post-haste.
Also, as always, two extra chapters are always available on Patreon: https://www.patreon.com/soggyredtoast
<< Previous | First | Next >>
submitted by SoggyRed to HFY [link] [comments]

With Open Eyes The Giant Stands

Welcome back.
Carrying on from [To Awaken A Giant You Must Open Its Eyes]
Continued on here [And So They Feared The Giant]
---

Sara Hiistaka of the Ithikitak Family strolled through the quiet suburb. The air was warm and the sky was clear - the star shone upon the happy world with its brilliance. In this warmth, bathed by their generous star, she walked at a leisurely pace while admiring the tiiska that were in bloom. Their brilliant red frills along the spindly leaves ending in a bright burst of orange with blue pollen. They wafted too and fro in the breeze, reminding her of the many years she’d been here while all her friends had left and gone to ‘human space’. ‘How I wish I could have joined you all among the humans’ she thought ‘it would be such an adventure!’

She arrived at the “Meteor Creamery” a human chain that had become quite popular serving iced dairy or substitute dairy with flavors that had never existed on Kiffitzial, the Uakataki homeworld. Chocolate, strawberry, raspberry, blueberry, cherry, and vanilla! She especially loved the vanilla flavor with cherry! It was themed after what the humans called the “Good old days” centuries ago, also known as the "Nineteen Fifties." She found the neon lights and the old jukebox that played “Classical Human Music” fascinating, and remembered listening to the one called "The King of Rock and Roll" on it all throughout her childhood.

Across the room the jukebox played “Jailhouse Rock” as she approached the counter. It was him! It was the human King! “The whole rhythm section was the purple gang! Let’s rock!” wailed the music while a holovid displayed the music video. She observed the menu after a moment's distraction. It had not changed yet for the warm time the humans refer to as "Summer". New flavors from Earth usually arrive, and she could hardly wait to try this new "Nutty Flavor Explosion" with "Pecan, Walnut, and Almonds Too!" She thought ‘I bet Gregory and Juunii both got to try it already, I wish I could be there!’ It was her turn in line now and seeing nothing special she went for her favorite. “I would like a double scoop, vanilla and cherry please!”

The antennae on the Uakataki taking her order twitched. He was dressed in a classic Earth milkman uniform with a paper hat. “Good choice as always Sara!” he went to the display to scoop out the ice cream. “I wanna stick around while I get my kicks! Let’s rock!” continued on the jukebox. As he knelt the hat began to slip from his triangular head, but he clamped it down with one antennae before it fell. “Damn things need a strap” he muttered. Coming back up with the waffle cone and a spoon he asked “Well Sara, would you like anything else on it?” She stood for a second, then shook her head.

“Nah, going for my classic. Thanks Tom!” Tom nodded as she swiped the credstick and handed her the ice cream. When the humans emerged into the void the Uakataki were the second species to greet them, after the Ghulatar (which had warred with them). The Uakataki had no want for war, and were classified in Earth records as “Second Contact.” The mantis-like race had fallen in love with the human culture, and over the last hundred plus years had adopted much of it that made sense - and some that didn’t. In exchange for this they guided humanity through the membership in the Pact as an affiliate in order to help protect them - although it later turned out they needed no such protection.

As they studied the humans they learned of their past, their endurance, their strengths and their weaknesses. The Uakataki had adopted the use of biomechanical engineering hundreds of years ago in order to enhance themselves and survive the harsh reality of the galaxy. Integrated voice boxes so that they could talk to other races, like humans. Integrated information systems to access the Uakatanet, like the human networks. Enhancements to their eyes so they could see in very dark conditions, better than humans could - although some humans now augmented this as well.

They also had tampered with their very genetic building blocks some thousand years ago, making their species more stable and more civilized. It was deemed necessary after the last wars had destroyed so much of their world two thousand human years back. In so doing they had become a different species and adopted the name Uakataki - meaning ‘Ascended Uaks’. However fragments of the older race did still exist. They proclaimed themselves “True to the Past” and referred to themselves as “True Uaks” then journeyed away on their pilgrimage to the center of the galaxy.

The True Uaks still had insect-like abdomens and four legs rather than two, while the Uakataki were bipedal, and had modified themselves greatly based on some unknown design lost to the past, and they moved the organs from the abdomen to their thorax while lengthening it. Most of the Uakataki were between 5 and 6 feet tall, with outliers. The changes had been drastic, but so far research into the records revealed little about why some of the changes had been made. A great information purge had occurred a millennia ago.

Although their tongues were thinner than a human’s and similar to that found on a terran bee, they sufficed for the consumption of the cold treat. Mandibles made short work of the delicious waffle cone after the ice cream was sufficiently excavated. Although Sara was not her birth name, it had become a custom among the Uakataki to adopt human names, something that had been done now for a century. They wore human clothes made to fit, watched human movies, absorbed human memes, consumed human goods, ate the human foods that they could, and adopted human customs. They knew what human ships looked like too.

The rich history of mankind was broadcast in all its forms - the Uakataki were voracious consumers of human media. Movies from the earliest point to their newest entertained billions and led to human social studies in their schools, and emulated media in their cinema. Stories of their own past that had been written or were verbal were produced as movies by the Uakataki. Humans had dubbed it “Uakawood” to great honor amongst the Uakataki. Many scripts were also used from human media. The latest to make the rounds was their rendition of “12 Angry Men” starring some of their biggest home grown stars, and a few famous (B actor) humans.

Mindlessly consuming the icecream she felt the fine fuzz on her neck tickle and stand on end. Something was wrong but she could not place it. She finished the cone and looked up. To her horror she saw ships burning out of the fold and into her planet’s sky - tearing the clouds asunder with their shockwaves. “Those are not the human ships… those - those are not human at all!” she screamed aloud. Other stopped and looked up, pupils going wide on their large eyes at the sight of the ships ripping apart their skies.

The first explosion rocked the city center miles away - the blinding light shocked the Uakataki at the ice cream parlor. Their eyes squinted as their pupils contracted at the brilliance. Sara covered her eyes rather than be a deer in the atomic headlights. After the flash died she stared at the massive mushroom cloud as it rose. More and more joined the chaos beyond it. Pillars of death signaled the end. She was struck by the realization that those were nuclear. They were not airburst. They were city killers. Dropped on to the soil to burn it, fracture it, and destroy whatever they touched. Their purpose was to inflict mass casualties with fallout and to sterilize the ground with radiation. Millions had just been vaporized, and more were to be vaporized as death fell from the sky.

Information flowed into the cranial implant which was worn by most of her race, bombarding her with news of bombs falling, warnings, alerts, and an overriding message to “SEEK SHELTER” Sara panicked, grabbed her bag and looked for Tom. He was already gone; now so was she - she ran as the first exhausted blastwave shook the buildings around her. The air wailed with stuttering sirens while emergency broadcasts broke on all electronic devices. She continued running and then remembered a place of safety from when she was a child.

Sara had always lived close to her childhood home with her great grandmother until she had passed several rotations ago. For a while Sara had idled in a sort of lost haze in the days after the funeral, she had dearly loved the old one. She had been alive from the times before the humans had made contact. Home is where instinct was taking her; past the little round house and grassy roof with the long hedges surrounding it. She jumped past the little garden her great grandmother had tended in her old age, past the chimes that had hung for a hundred years, and past the end of the pavement down the rolling hills. Down into the cool stream she spent many warm seasons she scrambled onward.

Up the stream to a small waterfall, then down the side of the small cliff. ‘Yes yes! That’s right! It is here!’ She remembered it! An ominous thud filled the sky as another city died in the distance. Screeching fighters streaked overhead, and were quickly silenced by being blown into billowing red clouds by the invader’s own fighters. her people's ancient fighters stood no chance. She hurried down the rocks and lost a shoe to a rock ‘Well, to hell with them’ she tossed the other one off as well. At the bottom she stood in front of the gaping maw in the side of the cliff. She ran her fingers over the mossy exterior, remembering the times she’d spent in the old cave as a child.

Another massive blast erupted behind her, the ground was lit as if their star had gone nova. She felt the burning on her neck. Sprinting inside she realized she was cut off from communication, only picking up static. She tuned the device with her mind to the radio - an ancient human tradition of music had brought it - and only heard hissing again. Deeper into the old cavern she ran to find sanctuary. Blast doors to a bunker thousands of years old, a relic of when her own species nearly wiped itself out. She used to play in the cave but was always scared to go beyond those ominous doors with their death-head symbols.

She entered now without fear of what may lay inside but rather what was behind her. She tried to pull the ancient blast doors shut. The monolithic doors stood silent, uncaring. Their rusted edges had slept for so long, they did not move with simple pressure. She searched in desperation for some way to close them. A sign above a metal box caught her eyes. In Old Uakian it read ‘Manual Override.’ Swinging the door of the old panel open there was a huge crank inside. She furiously began to pull and push on it. Amazingly the doors budged and began to close on their old magnetic bearings, a testament to ancient engineering during those dark times. It seemed to take ages for the doors to move and inch however.

As she cranked furiously she thought back to playing with her friends as a child. How they had dared each other to go deeper into the cave. How she had won by touching the door. How they ran when a spooky sound was heard. How they all left while she was forced to stay behind later on in life because of family. How they left for exciting careers among the humans… ‘Be careful what you wish for’ she thought to herself now. The doors creaked and rumbled along from outside inward.

She could hear the grinding of those ancient gears. The left door which must have weighed several tons completed its closure with a deep thud, and then clanked and locked into place. The right door stopped before it reached the end, letting just a sliver of light inside. Desperation and panic overtook her as the crank would turn no more. She grabbed at the door, trying to pull it in and shut it all the way.

Then a flash of light blinded her and the world went black.

---

A quiet suburb in Michigan woke to the thunder of an ancient beast. The earth trembled for a moment. Then was still again. Birds were silent while the air stagnated in anticipation. In the distance a black pillar of smoke rose as the ground thundered again. People left their homes and stared at the billowing black in the sky. They were pointing and wondering what and why. The sound rose to a crescendo again! Another pillar of black rose high in the morning sky. The giant was awake, the ancient factories were alive, the deep billowing black of carbon exhaled out from furnaces of hellfire.

It had been two days since the Earth watched the burning of Kiffitzial, homeworld to the Uakataki. One day since the President of the so-called United Earth’s Nations made his speech. A response fleet was rumored to have been sent already to aid them, but a media blackout persisted in all military action. Instead the footage shown was from drones, broadcasting the great work mankind had just started to undertake. Looking far above little dots scurried. Red dots in one direction, blue dots in another. Yellow dots and white dots roamed freely.

The workers of this massive industrial complex had brought their fiery dragon god to life after three centuries of slumber. It’s magnificent forge belched heat and sucked in the fresh air. On the ground the workers positioned the filtration system into the old smokestack after it had been cleared with a few pressure blasts, having shot pillars of black into the sky. Scaffolding surrounded them as reinforcements were placed, rings of nanocarbon stabilizers and materials.

Many others were undergoing the same transition from sleeping monsters of industry to awake and angry. A host of robotics were deployed into the ancient stockyards. Now the fires were fed by fusion, the stacks were being fitted for filtration on those that could not be converted. New piping and electrical lines were being run. New networking was being installed by a host of tradesmen. Roboticists programmed the machines that would help production reach new heights never before seen.

The supervisors were all recently in from Mars, Titan and Triton, places that still forged. They were teaching the lost arts to the tens of thousands who would soon take these roles on Earth, and who themselves would teach the art to more. While the massive ships would be built in orbit, the steel and iron to build the weapons of war would be made here on Earth. Weapons that would rain down upon the enemies of the EIDF-Third Pact alliance like rain in a summer storm.

All across the old industrialized lands factories were brought online. Some had been maintained by their corporate owners as cheaper than leveling them. Others were being rebuilt with modern modular manufacturing. Active factories that produced consumer goods began to dedicate lines to the manufacture of parts and materials for the war effort. This was the beginning, as the manufacturing requirements of a hundred million man military were massive. A consumer economy had no need for neatly packed rations, medical kits, accessory kits, or other tools like folding shovels or knives. A war economy hungered for these, and the conversion to full production would have taken years if not for urgency.

Deep inside the psyche of the humans a fire burned, a deep seated anger and rage. The people were willing to sacrifice, they were willing to ration, they were willing to do their part in the great effort. Thousands of their own had been turned to dust in that cowardly attack, and billions of others were vaporized all the same. To fight fire mankind would use fire. Fire brought man out of the dark into the light. Fire built weapons of war for millennia. Fire breathed in man’s earliest machines. Fire took mankind to the stars. Fire would bring them to the door of their enemies.

They would burn for what they did.

---

“Well, that tells us what happened to Kiffitzial, doesn’t it?” Xue Fucheng stated as he watched the broadcasts from the latest drone infiltrators. He knew something that the Admiral didn't, but until official word came... He avoided the topic of command. ‘They’re already assembling the Thirteenth my friend, the black fleet will be yours. I hope you’re ready…’ Xue thought to himself, staring at the aging Admiral.

Frowning Collingwood replied “An atrocity. This cannot go unanswered. What is the word Earthside?” Xue looked down at his data-pad “Universal anger, disdain for the cowards who did this, mourning for the humans who were visiting, and mourning for the Uakataki who were lost. Particular outrage over the thirty second frame where the three children were...” Xue trailed off as he suppressed the mental image of scorched children.

Collingwood nodded with a hand on his shoulder and stepped out into the comms room. Across the intelligence monitors the footage was being displayed in the dark room. The glow illuminated countless intelligence personnel as they filtered through the materials from the drones, and monitored media Earthside. Across the thousands of news networks a fervor was being whipped up. A thousand human colonies pledged support.

The EIDF awaited the results from the bureaucracy that ran the human governments in its mishmash arrangements. An emergency session was called, and within a half hour the declaration of war was confirmed. The president spoke on behalf of the workers, and their efforts to bring the manufacturing might online. To awaken “A Sleeping Giant.” There were rumors of a reorganized war government as well. 'Politics would always be a most human endeavor… possibly as old as war. None of the pact ever came close to our bureaucratic impulses...' mused Xue.

The economies that had been at peacetime production for nearly a century began the shift by the end of the day. Ancient shipyards roared to life, ancient foundries breathed fire, ancient corporations long dissolved were re-founded. A workforce of men, women, and robots began the work of war preparations. The ancient gods of industry would rumble to life one by one, and be manned 24 hours a day, 7 days a week.

Volunteers from a thousand colonies rushed into recruitment stations. There had been tens of thousands of humans visiting Kiffitzial. They were erased all the same with other visiting members of the Third Pact. Anger seethed among humans more ominously, rage and grief motivated tens of billions. ‘A terrible and ancient human giant was awake again with a fire in its belly. The war machine awake again! Our history of war stretches back to the earliest days of our kind, and so would it be now!’ Collingwood thought to himself 'It was going to be-'

“Admiral Collingwood?” He turned to face the young captain who derailed his train of thought.

“Yes Captain?” he asked. She withdrew an envelope from an attaché case and handed it to the Admiral “Congratulations Sir.” Collingwood, a man about sixty years in age had a rugged deeply lined face. Scars stretched across it that told of his service on the frontier. His shock of white hair was rather unkempt at of late. He’d fought pirates and suppressed small rebellions as a young captain and later in his career he led small fleet actions against larger organized crime outfits... But nothing ever this scale.

As a younger man he’d boarded his fair share of stolen ships and taken his thrashings. Always humans he fought - criminals. He gently opened the letter. For the first time in nearly twenty years he felt anxiety, he also felt cold. Xue smiled to himself as the old man turned pale - he’d known what was coming.

From The President of the Provisional United Congress of Earth
Dear Admiral Collingwood,
Congratulations on your promotion to Admiral of the Fleet. You are to take your ship with current company and organize a counter attack with the Thirteenth Fleet. We must show them who we are and that we can touch them.
You will be given the flagships EIDF Alpha and EIDF Omega as well from the Sixth and Seventh. With this your orders are to head to Hegemony Space. We entrust you with this mission. You have command of the First Fleet, Second Fleet, Third Fleet, and the Thirteenth Special Operations Fleet with its already assigned flagship EIDF God of Thunder.
The response to these demonstrable acts must be swift. You are to take all available forces and strike at the Goap-Qer and then commence a rescue operation of the remaining citizens on that world if any are left.
Godspeed
President George Andrew Kennedy
[Signature]

“Miserere mei, Deus” Collingwood stared blankly for a moment after his whisper, and placed the letter back into the envelope. He saluted and dismissed the young captain. Nodding to Xue, Collingwood walked to his quarters and shut his door. Wiping his hand across his brow and over his hair he sat down and read the letter again. After he placed it back into the envelope for a second time, he carefully tucked it away into his rucksack, and sat in silence.

Then he wept.

---

A crumpled mound of burned clothing and limbs began to stir. Then came a howl of pain that quickly devolved into mandible clicking and sharp breathing. Her blistered back was exploding in pain with billion needles at once. Her left arm was in pain as if it had been held in molten lava. Her legs were numb. Her antennae were numb. She could not see. She could not hear. She could not feel. 'How long have I been unconscious? How many hours? A cycle? More? How long have I been in here? Where even is here?'

Slowly feeling returned to tingling legs as her weight shifted and she managed to sit upright on the cold floor. She could feel her own breathing now. Her left arm was a ball of pain, everything below her elbow felt like an explosion that wouldn’t stop, and the numbness from her antennae frightened her. As she felt with her right hand she found her clothes were singed and ruined. ‘Am I blind? I can’t see anything!’ she thought to herself ‘but… I am alive.’ Taking in a sharp breath she realized what had happened. The bombs. The people. As she sobbed she realized the biomechanical implants were offline. Trying to calm herself, she waited for the implanted heads up display to boot. Nothing.

Darkness enveloped her in its absolute oppression. She tried to get the biomechanical parts to activate again. Her meshbox that allowed her to speak the tongues beyond her own didn’t register, even though it was much simpler than the rest. The integrated implants for her eyes were offline, as the Uakataki did not have a natural vision in very dark environments. No, no response from the heads up display integrator either after a second try. Nothing was happening with her internal thought commands either. ‘Turn On Authorization’ she kept repeating in her head. Nothing. Silence. ‘And why does my hand hurt so much’ as the pain kept coming in searing waves making her nauseous.

She adjusted herself again, slowly pushing herself backward with her powerful legs until she could feel the cold wall near her back - but she dared not press hard. Something was wrong. Very wrong. All over her body things were not right!

‘Start with the legs’ she thought to herself. She moved her feet, and her legs without issue - although they still tingled a bit from being ‘asleep’. The carapace appeared to be intact, no leaking of blood, and the membrane over the segments on her legs was still intact. It was similar to human skin with a similar function. Below the membrane were the plates of carapace and parts of plated chitinous outer skeleton, below that was flesh and muscle, and deeper were bones.

She felt her hips and side, still nothing but light burns, although her clothing was ruined tatters. Taking a deep long breath she slowly felt down her left shoulder, and that hurt. Further down with the lightest of touch she felt around her elbow, where the pain was starting to be the greatest. ‘Maybe I broke my arm, or my hand?’ she thought. Then she felt it - or rather, the lack of it. There was nothing after her wrist. Her hand was gone. ‘What the fuck!?’ she began to panic again.

She gently grasped at her left wrist, and felt a rough charred stump - no hand at all. Protrusions that were hard. 'Bone?!' Her hand was gone! She panicked even more, breathing rapidly, she felt for liquid, but could find none leaking. The burn was thorough. ‘When I was trying to... the door… my hand was caught by the door… that is… oh no’ she thought to herself. ‘The radiation… what have I done to myself?’ she shuddered and vomited with fear of radiation sickness.

Instinctively Sara leaned back as she sobbed and shivered, feeling cold and alone. She was rewarded with searing pain in her back again ‘What!?’ Quickly she pivoted as best she could, but turning caused pain too. She tried to move her wings - maybe they had been damaged by the fire when she was knocked down? They weren’t functional anymore for her species, the Uakataki had lost flight eons ago when they were a smaller and more primitive species, but they served a different purpose in their society since it advanced. Mostly for showing off and attracting a mate. Mostly.

The long wings usually extended down their back from a set of joints just below the neck and acted like a small cloak. They were also very flexible and provided some padding to the back when sitting in chairs. Human chairs were actually more comfortable than one would expect for a Uakataki, as they did not extend far enough to get caught when sitting. She felt her back with her right hand… hers were... gone. Burned away… ‘No no no no! No!

She passed out onto the cold floor with a thud.

---

The un-mothballed God of Thunder orbited above Io, being joined by the Alpha and Omega. The God of Thunder was the largest wartime ship that was in service, it was eight miles between the stern and the bow, shaped like a blade in the stars. It’s kinetic force weapons took up the center of the massive ship with four giant tubes to fire tungsten rods, while the port and starboard boasted smaller side facing tubes that could rotate on turrets.

All around the ship were kinetic weaponry for anti-ship or missile fire, tubes for torpedoes, tubes for missiles, docking ports for other ships and hangars for the fighters. There were hundreds of automated .50 cal turrets modified for space combat. It carried a complement of 128 gunships for atmospheric combat, 222 bombers, 566 fighters, 200 utility craft, and an untold number of drones in the interceptor, locator, and freedom classes. The powerhouses of the ship were the fusion reactors, along with massive backup systems and cooling lines. Crew quarters in every section ensured that there would always be hands available somewhere. The ship hosted twenty thousand at full capacity, and could hold twice as many temporarily for ground action. This would be the first time it ever saw combat outside of war games a century ago.

It was antiquated however, built after the Ghulatar war and the fear of more hostile aliens. The same could be said for the rest of the fleet’s massive super carriers. The Omega and Alpha were around two thirds the size of the God of Thunder, and they were sister ships even older than the pride of the fleet. The aptly named the kinetic super weapon used was the Hammer of God, as it could fire a payload heavy and fast enough generate multiple megatons of damage with the upper limits unexplored. Various dozens of other ships joined the combined fleet, and Fleet Admiral Collingwood met with the commanders of each vessel in the great hall.

“We are to surround the planet, we will stage outside of their weapons range, and then fold right atop them. Omega will take the northern pole. Alpha will take the southern. Fighters will be deployed from both, while the rest of the fleet will approach from all angles. We’re going to throw everything we’ve got, and when they bunch up the God of Thunder will fold in behind their capital ship. From there we will launch everything we have at it. If we win gunships are to search for survivors and pick up anyone we can as prisoners. We will also search Kiffitzial ” He paused, looking at the holodisplay of the world. Such horror.

“If we get overwhelmed we will need to beat a retreat - we will split into two groups and jump in opposite directions, drawing them away in the confusion.” The grim men and women nodded. “In order to avoid alerting the enemy, we will be folding to these areas outside the system itself, then making the fold inward.” the display simulated the action of around fifty ships appearing around the planet, then thousands of fighters deploying. “With any luck we’ll catch the so called Infinite God with his many pants down.”

The gathered captains left the room hours later, the briefing done in exceedingly excessive detail. They would depart for the first fold positions soon. Then, after confirmation through the fold comms, they would begin the attack on the Goap-Qer. The time of reckoning was at hand, the ships were uniformly painted black during their final preparations by an army of assisting drones. They would appear out of the void like blades through black oil and stab at the Goap-Qer when they least expected it.

The Black Fleet evaporated into the void.

---

“You see cousin? Not a single response. What, a few recording devices to make sure we’re as strong as we say? Pah!” The Infinite spat green mucus and continued “We’ve done what we needed to do. Set a course and take me home. I need to greet my people, I need to hold my Triumph! We will have a hundred days of games! Yes! We will have games! Hahaha!” His many legs undulated as he stridulated in his joy. “The best part is, we don’t even have to occupy this world! Let your trainees mop this mess up for now Cousin. The people need to see their Great Marshall and their Infinite God Emperor!” An expression that could pass for a smile lit up his face.

Then he belched loudly.

‘One day…’ thought Great Marshall Hekguzi ‘One day you’ll choke on one of those slaves and then…’ he caught himself, and nodded to his corpulently long cousin “Of course, they must see you and I... for the morale. We will depart with the bulk of the fleet. I will leave Commander Ocburth in charge of the cleanup” then internally to himself ‘because if anyone could need some training it is him.’ The fleet dropped a few more fission-fusion-fission bombs just for good measure, and began to depart.

Their massive bloated ships moved outside of the planet’s gravity well and entered foldspace leaving Commander Ocburth and his XXII Legion in charge of the survivors. Orders were to hunt down any remaining, kill on sight, and train. They would be on their way being a serious legion once they’d completed a few more cycles, and a new legion would start, the XXIII Legion. This would become the next training legion and Ocburth would be promoted to Marshal of the XXII. Much smaller than the higher ranks due to his age he was eager to prove himself. “I will reward anyone who brings me the head of one of the filths a tektar. If you find a human and bring me a head, ten tektar!” A day passed, only a few tektar were rewarded.

The hunter-fighters continued to do their dirty work, and Ocburth was going to raise the bounty. “Can they hear me?” he looked over at a commsman. The commsman looked back with an expression of confusion. All his screens began to go blank, static filled the communication lines. Out of the darkness stars began to vanish, their vision occluded by something in the distance. By the time they realized the truth, a great storm erupted. The vantablack ships consumed light, and hope.

The fire began. All around the remaining massive ships fire erupted, fire to cleanse the skies of the monsters who burned a world on the orders of a mad creature. Fighters scrambled as ships burned or broke apart into the void - their fires extinguished when atmosphere was vented into the void of space with little silent puffs. “Pull round to face the enemy! Pull round! Take the one at the polar south! Fire! Fire damn you! Put everything you can into it!”

Streams of atmosphere vented as fuel ignited from missiles, they shot out and then headed for the Alpha. The Alpha’s decoy field of drones managed to destroy and detonate most of the missiles as they spun about. The Alpha flashed back in little balls of dissipating silence as torpedoes left their tubes. Little balls of fire went dark again before smashing against the shields of Ocburth’s flagship.

“Alright, we’ve got their attention! Deploy strike teams!” Admiral Abraham of the Alpha shouted out over comms, then looked down “Fire everything you’ve got!” then released the communications relay button. He watched as puffs of debris silently filled the sphere around the ships. They had drones for days to intercept the incoming fire, they had shields, they had anti projectile kinetic weapons… and yet something still felt… ‘it must be nothing’.

As each color-coded squad launched, the red strike group began “This is” -snicker- “red leader, do you copy!” over the channel “Copy red leader!” came dozens of replies. “Alright… I’m not gonna lie, I’ve always wanted to say this… All wings report in!” Across two dozen strike craft men and women smiled as they replied.

“Red Two standing by!” almost cracking he thought to himself ‘Fuck yeah, come get some.’
“Red Three standing by!”
“Red Four standing by!”
“Red Five standing by, this is out of order from the movie!”
“Red Six standing by, this is a real combat mission nerd”
“Red Seven standing by, I don’t get it”
“Red Eight standing by, of course you wouldn’t Porkins”
“Red Ni-”
“Hey! Don’t call me Porkins!”

“Comms everyone! Continue reporting in. Show some discipline damn you! We’ve all seen Star Wars!” He couldn’t help but chuckle after turning off communications. This had to have been done on purpose.

After the checks Red Squadron was deployed into the black. Projectiles flew in maddening chaos as kinetic shields blocked most, while others bounced off of the fighters. They swooped in and began dog fighting around the slow fighters of the enemy, they almost moved too slow to effectively engage with the rapidity of their own ships. Humanity had over-engineered its space fighters to a degree, so on the fly tactics were employed.

After another round of missile weapons were fired at the human ships. Abraham ordered to pull along side the bloated capital ship that kept launching missile after missile at them. It dwarfed them, but that wasn’t what concerned Abraham. What concerned him was the strange glow it was generating from the front, and he’d rather not find out what that was “Open up full broadside, keep hitting them in the middle! Focus fire! Focus fire!” He watched, and realized that he might have an ace up his sleeve.

“All units, employ EMP shielding and withdraw. Preparing EMP torp assault. Ten seconds” the fighters broke away and began to flee from the capital ship.

“Look at them! They’re retreating! Ha! Human scum cannot break us, prepare the particle weapon. We’ll swing around and end this, then mop up the rest!” Ocburth crowed. His subordinates did as they were told and prepared the particle weapon. Outside he saw fighters chasing down the humans - although he had to admit the human fighters were far faster than anticipated. “Speed won’t save them. Nothing will. I’ll ask if we can be the ones to go to their pathetic homeworld and burn it when we find it!”

“Five seconds” The massive capacitors hummed as they were charged in their torpedo tubes. Each one beginning at a low frequency until they reached a fever pitch. They screamed out in a hellish whine before their explosive charges launched them into the vacuum. In all directions the tiny black dots puffed out of the Alpha. Then again. And again. Hundreds of them prepared and moved into a semi-sphere, before firing off using a small nuclear propellant.

Silence. The glow died. The massive capital ship began to list. The shields were gone. The last emotion Ocburth felt was terror.

Out of the black the much larger God of Thunder stalked silently in its infinite blackness. Four bright lights were seen at the front. The Hammer of God deployed four tungsten kinetic weapons weighing fifty tons each. With a sudden burst, the bloated vile capital ship mushroomed outward as the fusion cores inside blew. Fire briefly enveloped the massive capital ship as its atmosphere ignited, and then it was no more. Now trillions chunks of metal and debris floated out in an expanding sphere.

The enemy fighters slowly floated away in random directions as well, their own systems disabled. “Clean this mess up.” ordered Admiral Abraham. They complied, and massive blooms of atmosphere began to vent from fighters as they “popped.” The great holoscreen on the deck of the God of Thunder came to life “Fleet Admiral, we know their weakness. They do not have effective EMP shielding it appears. I recommend exclusive use of EMP weaponry to disable, and traditional to destroy.” He saluted and Collingwood nodded.

“Alright, you heard Abraham. Broadcast that. Employ the imps!” Collingwood smiled, he always liked calling them imps. Across the Thirteenth EMP weapons were employed, as were the few radiant dishes on the Omega, disabling incoming fighters, and then torpedoes doing away with the other large ships. Within the hour the entire fleet was wiped from existence, only a few fighters remained. Then they too popped.

“Casualty report sir!” a datapad was handed to the admiral. On it listed only 44 human casualties after all the fighting, while estimates of enemy casualties being in between 120,000 to 240,000. Estimates of survivors on the dead planet’s surface were currently unknown, the nuclear hellscape that was below them was difficult to penetrate - the amount of dust in the atmosphere gave the planet a sickly appearance.

“I don’t know how anyone could have survived down there” he said staring out the viewport at the dying world.

---

Inside the old bunker,one of the world’s last breathing inhabitants remained in the darkness.

---

Hope you all enjoyed the second installment!
submitted by MetaVulture to HFY [link] [comments]

2020 Psychedelic Industry Insights Report

2020 Psychedelic Industry Insights Report
By: Nikita Alexandrov BChem, MBA - CTO, ThinkMyco
[[email protected]](mailto:[email protected])
Jan 8th, 2020
2019 was a pivotal year in the psychedelic industry with US decriminalization actions, two companies receiving FDA breakthrough status for psilocybin, funding of the $16M Johns Hopkins Psychedelic Research Center, The US Defence Department starting their rumored $20M+ Focused Pharma psychedelic science program and the movement of top universities into research and clinical trials. With the explosion of the more than $100M dollars worth of investable psychedelic opportunities in Q3 2019, the collapse of high quality cannabis investments, one of the best decembers on record and a potential $1B scale psychedelic IPO - 2020 will be the year of psychedelic investment.
The movement in the field recently is just a blip compared to what is to come, this industry has been brewing for the last few decades. Big Pharma has failed when it comes to new approaches to brain and central nervous system treatment. Neuro drugs have half the success rate of all Pharma projects, which caused most of the big players to liquidate their neuro programs in the last decade. Recently, engagement is exploding with new clinical legislature supporting neuro, the recent approval of 3 potentially blockbuster neuro drugs in the last 2 years, Q2 2019 saw a record of over $320M in investment into neuro drug development. Interestingly enough an influential group of ultra-high net worth individuals to funded the psychedelic holding company Atai Lifesciences which went on to fund Compass Pathways and continues to fund commercial efforts in this field. Atai Lifesciences recent movements are a familiar story of acquisition and consolidation in an emerging market which will be a common theme in the future of the psychedelic industry. The collapse of investable cannabis opportunities are driving investors comfortable in stigmatized industries and binary risk to the table with big pharma, cutting edge science and huge unmet market needs to create a perfect storm of opportunity.
Highlight:
Investors seek 'mega blockbuster' drugs as neuroscience undergoes renaissance
How big is the Psychedelic Industry?
Historically, the psychedelic industry has been fragmented with around $60M worth of companies in the last 20 years, many of which were not sustainable. The current industry is around $300M worth of investments, dominated by the Peter Thiel backed Atia Lifesciences at $100M+ and Compass Pathways at $50M+, followed by Mind Medicine at $10M+, Fieldtrip Ventures at $10M+ and then a 10-15 early companies in the range of $2.5-10M each. The $300M worth of investable deals have only existed since the public formation of Compass Pathways in 2016, with the majority leaving stealth mode in 2019.
Highlight:
Transforming psychedelics into mainstream medicines
How big is the Psychedelic Market?
The psychedelic market is emerging while highly coupled to clinical/regulatory events and is split between recreational and medical psychedelic markets:
Recreational: $8-19.2B
Calculated from cannabis market and comparable usage prevalence as well as demand size economics.
Medical: $373B
Calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
Highlight: Analysis of the Psilocybin Pharmaceutical Market
Who are the players?
Atai Lifesciences - German based, Global psychedelic pharma holding company formed by ultra-high net worth individuals and big pharma, $150M+
Compass Pathways - London based psychedelic giant, Atai's bet on psilocybin as an approved drug for depression, $50M+, IPO 2020
Usona Institute - A Wisconsin based non-profit powerhouse competing with Compass Pathways to approve psilocybin for depression.
Mind Medicine - Toronto based ibogaine derived addiction drug development company taking their lead candidate 18-MC through the clinical approval process, raising $15M, RTO in 2020
Eleusis Benefit Corporation - New Orleans based discovery/clinical stage Psychedelic pharma company supported by industry scientists, raising $25M
FieldTrip Ventures - Toronto based, Aurora backed magic mushroom research and development company building clinical and production infrastructure, raising $10M+
ThinkMyco - Vancouver based holding company developing disruptive mushroom production technology and next generation therapeutics, raising $5M+
Gilgamesh - Psychedelic drug discovery company affiliated with the Atai owned Perception Neuroscience and Columbia University, raising 10M+
Universal Ibogaine - Vancouver based Ibogaine clinical development company franchising the world's most advanced ibogaine clinical model, raising $10M+, RTO in 2020
PsyGen - Alberta based psychedelic mass production and clinical research company with highly experienced production chemists $5M+
Entheogen Biosciences - Vancouver based company pursuing psilocybin and DMT based drug development, raising $3M, IPO in 2020
Salvation Botanicals - A Vancouver based company touting a private controlled substances site license and supporting clinical research, raising $10M+, RTO in 2020 Numinus Wellness - Vancouver based wellness company building testing as well as clinical infrastructure, partnered with Salvation, raising $5M+, RTO in 2020
Cybin Corp - Toronto based research and development company building drug development and production infrastructure as well as nutraceutical assets in legal jurisdictions, raising $3M
Emerging Players - There are a number of emerging players, around $25M+ in emerging deals in Q3 2019 which have not passed due diligence.
Clinical:
Recent data is showing psychedelics can be real mega blockbuster neuro drugs. Johns Hopkins recent trial on Psilocybin for smoking cessation showed an 80% success rate in terminating nicotine addiction, more than double any known therapeutic approach, including nicotine replacement therapy. Academic data shows that Ibogaine is 95% successful in terminating acute opioid withdrawal/addiction. Limited data from Ibogaine for opioid addiction trials show 50% success rates in terminating addiction, more than 10X higher than the generous 5% success rate of other approaches. Data from leading Ibogaine providers like Universal Ibogaine show that this 50% figure can be pushed closer to 75% with proper protocols and aftercare. Clinical trials on Psilocybin for cocaine/crack addiction are ongoing at the University of Alabama at Birmingham, a top 20 medical research university. 10 patients were un-blinded for bioethics review and the unpublished data shows that 30% never touched cocaine again while the other 70% had a relapse or two and turned their lives around, showing a 100% success rate in changing lives with minimal cost. When this data is available publicly in the next years, tidal waves of interest will move into the field.
Highlight:
Psychedelic Clinical Research Timeline
Projections:
As a recreational market, 0.1% of the population was surveyed as using psychedelics in the last month, placing the current black market at $19.1B while as a comparable percentage of the legal cannabis market adjusted for prevalence would place it at $8B.
As a medical market, the $373B neurogenics market seems to be the addressable market. Penetration into any indication in the neurogenics market would reap vast rewards, Psilocybin is on track to compete in the depression market with two FDA breakthrough designations, a 2% penetration into the depression market would being $1.4B in value. Ibogaines very reasonable projected 4% penetration into the opioid dependence market will bring $9.6B in value yearly to groups like Universal Ibogaine which are deploying clinical infrastructure, supporting clinical trials and controlling the Ibogaine supply chain. Of all of the indications in current psychedelic clinical trials, not considering crossover, they address a $400B+ market, with projected penetrations across each indication and adjustments for market factors, it is projected $16B+ of value yearly will be created from commercialization of current late stage clinical trials.
Highlight: Johns Hopkins Psilocybin for Smoking Cessation Data
Challenges:
Regulatory Challenges:
While nearly 100 cities are creating legislation to decriminalize psychedelics and multiple US jurisdictions have passed decriminalization, federal changes will be required to open legal markets to the full potential. While investing in the binary risk of regulatory changes is standard in the junior markets, current regulatory controls are preventing early revenues. Many Canadian companies building production and distribution infrastructure offshore in jurisdictions such as Jamaica are operating in a legal grey area. While it is legal in Jamaica, any benefit or advantage given to a Canadian company could be considered a proceed of crime including IP development, capital repatriation and validation of technology offshore. Section 56 exemptions from Health Canada are required for Canadian companies working with psychedelics offshore and companies which are raising investment dollars without a secured Section 56 exemption may be incurring legal risk.
Cardiac Liability:
The unspoken elephant in the room of psychedelic derived pharmaceutical acceptance is not regulation, for example Ketamine is a scheduled drug which was recently approved. The problem is actually the liability of bringing a seratonergic based drug to the market like Psilocybin, DMT and LSD. The crippling withdrawal of blockbuster drugs Fen-Phen and issues with other drugs like Imitrex due to seratonin agonist effects on the heart have scared the FDA into a position that any seratonergic drug will require extreme cooperation and diligence and will absolutely incur additional clinical and monitoring costs over other drugs. Psilocybin while technically hitting the 5ht2b receptor which causes cardiac side effects, does not have a high enough affinity to be a deal-breaker, meanwhile LSD having a very high affinity will cause large barriers for groups attempting to bring microdosed LSD to the market. Ibogaine suffers from cardiac liability due to an entirely different mechanism and unlike Psilocybin or LSD, adverse events have been reported. While Methadone and other standards of care also have the same long-QT cardiac liability at much higher rates and significantly higher mortality rates , Ibogaine clinical models must pre-screen patients for existing heart defects before procedures to guarantee no adverse side effects.
Banking/Insurance/Exchange Issues:
Legitimate psychedelic derived drug development companies have already had bank accounts halted at multiple banks for involvement in this industry and moving forward similar challenges faced by the cannabis industry should be expected. Exchanges and public offerings will have logistic challenges with this industry and minor friction has already been seen in the listing process. DNO insurance and other underwriting will be required to list in large markets and to date no psychedelic company has been underwritten, although underwriters and leading insurance brokers are actively exploring his industry.
Reimbursement:
The real whale will be insurance and single payer reimbursement of psychedelic derived pharmaceuticals on the market, allowing for global market uptake. Health systems have traditionally been decades behind the state of the art as seen in the point of care and home diagnostic device market, a market which could keep people healthy at minimal cost but has been crippled by lack of reimbursement.
Supply Chain Commoditization:
The production and control of psychedelic supply chains which is the familiar play of the cannabis industry will be a race to the bottom with magic mushrooms and other psychedelics. Production models are competing with a much more fluid black market and are being cannibalized by low cost home production and wildcrafting of psilocybin mushrooms. The LSD or ergoloid supply chain is highly monopolized, with the majority of the worlds ergoloids being produced in a single location.
Companies competing in the production and supply chain space will face heavy price pressure and a highly coupled global regulatory system. The single outlier is Ibogaine, with a current global use estimated around 90kg, expected to reach 280kg in the next two years, this is a commodity whose price will drive through the roof. Large ibogaine producers have stopped production and natural sources are not commercially viable, with an Iboga plant producing maybe a single dose on the 10 year period, the move of ibogaine to endangered status in 2019 and no synthetic GMP producers - the ibogaine market is legal in the majority of the world and exploding while highly underserved and fragmented.
Delivery System Challenges:
A number of recent psychedelic deals are built around new drug delivery systems for psychedelics entering the recreational market to build expertise and infrastructure ready to move into the pharmaceutical market. Many of these technological approaches will not translate from the recreational market to the pharmaceutical market such as CBD/psychedelic compositions, natural product compositions as well as vaporizer and inhaler based delivery systems. While 20%+ of all new FDA drug entities are derived from natural products, natural product mixtures containing many products and a controlled substance have never and will never be FDA approved due to the regulatory system. Companies developing Psilocybin/CBD combinations and related therapeutics for the recreational market should understand that unlike the cannabis market, recreational approaches will not translate directly to medical approaches.
Opportunities:
Syndicated Investments:
One of the largest opportunities in any emerging market is syndicated investment, a 2002 analysis of 584 venture backed exits showed that syndicated investments produced double the rate of return of non-syndicated investments. Psychedelic research and development companies require standardized infrastructure that can be leveraged across a number of players. The big players entering the industry are more interested in empire building, requiring massive consolidations of commercial efforts which can be facilitated by syndicated investment groups. Companies like ThinkMyco, Entheogen Biosciences and Cybin Corporation which focus on technology development, IP Portfolios and early stage drug discovery will benefit the most from syndicated investment and collaboration. A Harvard Business School review of Pharma discovery programs statistically compared drug discovery programs to weapons research programs and found in these high reward/low incremental cost programs the optimal path is to run parallel programs, with an average Pharma drug discovery program having 16 parallel programs, 10 core and 6 low budget/high risk.
IP Portfolio Development:
IP development is the highest value for dollar on the investment value chain and the psychedelic industry will be a totally IP driven industry. The most valuable patent portfolios will include new psychedelic compositions and therapeutic mechanisms, which require significant investments into fundamental R+D, while less competitive portfolios will include delivery system/psychedelic combinations.
A recent review of patents related to psychedelics shows many hundreds of patents for psychedelic derived therapeutics with only a small cross-section being commercially competitive. DemeRX, the $40M+ Ibogaine research company holds 65+ patents in the ibogaine therapeutic area. While DemeRX filed for bankruptcy and their research and development assets were liquidated, it is rumored they have been injected with enough capital to come back to the party - this is a dark horse to keep an eye out for.
Mushroom/Protein Connection:
The real opportunity in magic mushroom production models is flying under the radar: protein production. Mushrooms are one of the highest quality sources of nutrition and protein, if you took a vitamin C supplement you can live exclusively off mushrooms. Dried mushrooms have basically the same protein percentage as beef and in terms of grams of protein per acre per year are 100 fold higher producers and much more sustainable than traditional agricultural practices. Companies in this space which invest into real R+D for lower cost mushroom production will get a lift from the $1.8 trillion dollar protein market. A recent review of mid-sized mushroom farms shows that 50%+ of the cost of mushroom production is due to labor and technical inefficiencies. If energy, labor and materials cost drivers can be reduced, and the cost of growing a pound of mushrooms can drop from around $2 to around $1.20 through automation, mushroom protein becomes significantly more competitive than many of the industry leaders in plant based protein like pea protein. If energy cost reductions can drop the cost even further, mushrooms will become a disruptive food source. Psychedelic companies building mushroom production infrastructure will be well served to remember that by investing in automation, new technology and new growing systems the price of mushroom based protein production can make it more competitive than any other food source. The largest food security report in history was released Q2 2019 and showed that without subsidies a hamburger would cost more than 30$ and the meat industry will economically collapse by 2040, the protein game is looking more and more attractive as a hedge against the regulatory risk of magic mushroom production.
China:
China is one of the most advanced markets in terms of size and pharma spending, as well as venture investment. Traditionally the Asian cultures had no interest in marginalized and politically tense areas such as drug medicalization but the movement into CBD and China's rabid interest in plant medicines may create a large influx of Asian capital moving into psychedelics. This industry shifting action will be leveraged by education and the court of public opinion. A dialog must be created showing psilocybin as a plant medicine and not a drug of abuse. Interestingly enough, Chinese firms have very recently started producing magic mushrooms industrially and importing them into the Canadian market where they are sold into the black market over-the-counter in some Canadian herbalist stores.
Ibogaine:
Ibogaine is the only psychedelic model which will not be very quickly commoditized. Ibogaine as a solution to the opioid problem is a disruptive technology, with the rise of fentanyl and fentanyl analogs like carfentanil dominating global supply chains, Buprenorphine, the preferred standard of care is no longer effective. This is due to the aggressive affinity of fentanyl to receptors, the lack of tolerance ceiling and the little understood metabolism of next-generation fentanyl analogues, dramatically compounding a problem already at pandemic levels. Ibogaine supply chains have collapsed at the same time that demand is growing exponentially, the firm which dominates the current global ibogaine supply chain will reap around $1.4M/mo profit serving the current global demand. One of the largest African Ibogaine brokers has seen a 30x increase in sales from 2017 to 2019. With Universal Ibogaine taking Ibogaine through the Canadian clinical process and the grassroots support from Health Canada, Ibogaine will be the first psychedelic approach available to consumers. While Ibogaine is a scheduled drug in the US and some European jurisdictions, it is not scheduled in Canada and the majority of the global market. Multiple Ibogaine documentaries are in filming, including actors such as Johnny Depp, as this is an education driven industry, we should expect exponential growth to accelerate in 2020.
Support Industries:
Industries supporting the growth of psychedelics will be a large part of the future landscape as was seen in the cannabis sector. A psychedelic business support network including education, conferences, business analysis and financing have already cropped up commercially. In Q3 2019 the renowned Cambridge House International Extraordinary Future conference created a panel for psychedelic opportunities. Two weeks before the conference there was a frantic rush and the majority of relevant psychedelic players were represented last minute in the panel discussion including: Compass Pathways, FieldTrip Ventures, Mind Medicine, Johns Hopkins, Dennis McKenna and ThinkMyco. Multiple psychedelic investment funds are forming alongside of industry press, consulting groups and other support interests. In Q3 2019, Dr. Matthew Thompson of Johns Hopkins and Dr. Charles Nichols of LSU/Eleusis Benefit Corporation helped organize the inaugural conference for the new journal called International Society for Research on Psychedelics in its home of New Orleans. Over 100 international scientists from top universities were represented, with the conference having to turn down many late registrations. Dr. Rolland Griffiths, head of the Johns Hopkins Psychedelic Research Center said "This was the best scientific conference I have been to in my entire career.".
Sub-perceptual dosing:
Microdosing was popularized by Silicon Valley, catalyzing the resurgence of the psychedelic industry but microdosing is a protocol built on unsound fundamentals. Research shows that the therapeutic effects of psychedelics are highly dose dependant, higher doses lead to better therapeutic effects. The microdosing supply chain model has excellent returns, with a pound of mushrooms costing less than 5$/lb to produce which provides around 1200x microdoses. When dosages increase past the perception threshold, the potential for adverse events such as bad trips exponentially increases. The ideal dosage seems to be just under perceptual threshold where you can still go about your day, but much higher than a microdose. This is industry standard with seratonergic pharmaceuticals, an example being the diet drug Belvique, which is closely related to psilocybin, dosed at the perceptual threshold for maximum effectiveness. Belvique can cause psilocybin like hallucinations if 4 tablets are taken as it is a seratonergic drug. High doses of psilocybin require a clinical infrastructure and in-patient experience, dramatically increasing costs and logistics overheads. Sub-perceptual dosed pharmaceuticals will be available for out-patient and take home treatment and in many cases may be as effective as full blown psychedelic experiences. Mind Medicine, ThinkMyco and Eleusis Benefit Corporation are leading the charge in sub-perceptual therapeutics.
Next Generation Drug Development**:**
Mind Medicine is taking the approach of engineering the hallucinations out of the therapeutic experience by removing parts of the molecule and are moving their drug, 18-MC through the clinical process. This is the ultimate high risk/high reward play in the psychedelic industry. 18-MC is modified which also changes a variety of important receptor binding effects. The modified receptors include the receptors responsible for growth factor release, cognitive effects, cardiac effects and the opioid system coupled NMDA receptors. Since there is no data on the human use of 18-MC in opioid addicts, significant capital must be deployed before it is even known if 18-MC is as efficient as the parent molecule Ibogaine for treating opioid addiction, the ability to treat addiction in an out-patient setting with no cardiac toxicity - 18-MC will be the megablockbuster all investors in the neurogenic space are waiting for. ThinkMyco, Gilgamesh, Mind Medicine and Eleusis Benefit Corporation are leading the field in next generation drug development.
Lateral Drug Development:
While psychedelics address a $373B neurogenics market, companies such as Eleusis Benefit Corporation are showing they can address other unmet clinical needs such as chronic inflammatory disease. Eleusis is developing new psychedelic compounds for the treatment of inflammation, specifically within ophthalmology, and has recently published Phase I trial results revealing the safety and tolerability of low dose LSD in healthy older adults, with the intention of evaluating low dose LSD as a disease modifying therapy in Alzheimer's disease. Eleusis Benefit Corporation looks poised to cannibalize the $3B steroid therapeutic market. Not yet published research is showing Ibogaines potential as a therapeutic to treat sleep disorders. Johns Hopkins is currently reviewing the application of psychedelics in pulling patients from comas and vegetative states. The original pre-Mind Medicine clinical trials on the Ibogaine derivative 18-MC showed promise in treating Leishmania infection. BOL148, an inactive form of LSD, originally the placebo in human clinical LSD research, was found to in some cases to permanently terminate cluster headaches after a few doses and is being publicly demanded from the cluster headache community. These are the earliest days of understanding the application of psychedelic derived chemistry as new therapeutic approaches.
Public Health Engagement:
Looking at recently released data representing North American, working class adults, methamphetamine and fentanyl use is growing enormously and consistently. Linear regression of growth rates over the last 5 years projects a 380%+ increase in Fentanyl usage the next 15 years, with Methamphetamine projected at a 475%+ increase. This is concerning as there are more than a million high quality data points over 5 years and an R2 value of 90%+ which paints of picture of statistical certainty. This shows that the opioid crisis has moved from a lift caused by supply side drivers to an organically growing demand side driven pandemic fueled secondarily by histories cheapest and most available synthetic drugs. With $100B+ in fines projected for the opioid crisis in the next few years, state jurisdictions will shortly receive an enormous amount of cash that will be legally obligated to flow into anti-addiction spending. Due to poor outcomes and non-scalable approaches around advanced public health programs, there will be a flurry of legislature to address how to spend the $100B+ anti-addiction warchest. Players like Universal Ibogaine who have proven clinical models, can deploy infrastructure and guarantee statistically better outcomes will receive unprecedented amounts of non-dilutive government funding and will be the first to benefit from Decriminalization/Medicalization in the North American market. Players that can come to the table now at the state level and propose medicalization legislature as well as profitable clinical infrastructure with proven outcomes, could monopolize the entire US market. FieldTrip Ventures is developing Psilocybin clinical infrastructure while Universal Ibogaine is deploying proven clinical infrastructure already developed and proven by Clear Sky Recovery, the leading Ibogaine clinical experts with thousands of successful detox procedures and no critical adverse events.
Closing:
Like any emerging industry, there are challenges and growing pains but the blue-sky upside is unparalleled. "Black swan events are characterized by their extreme rarity, their severe impact, and the practice of explaining widespread failure to predict them as simple folly in hindsight." Due to changes in public opinion, a mental health and addiction pandemic as well as enormous movements of liquid cash, this sector is poised to explode in 2020.
Additional information requests: [[email protected]](mailto:[email protected])
submitted by mindovermatterlondon to Drugs [link] [comments]

Best Vaping Affiliate Programs Vaping is a new but hot vertical market. The worldwide vape & e-cigarette market was valued at $10mil in 2018 and is expected to grow at a staggering 25% from 2019 to 2025. Learn more about the Zamplebox vape juice affiliate program here. Vapor Beast Affiliate Program. At Vapor Beast, you will find more than 100 different brands of electronic cigarettes, tanks, mods, and e-liquids. Vapor Beast offers free shipping on orders over $35. They are based in California and have a fully staffed US based customer service team. Best Affiliate Commissions in the Industry. 20% payout on E-Liquid sold * (Lifetime Residual); 15% payout for all VaporFi Starter Kits, Cartridges, and Accessories sold & 10% Payout for all 3rd Party branded Devices; Refer A Colleague - Receive 5% of Sales from ALL Affiliates you recruit Join our affiliate program and start earning money for every sale you send our way! Simply create your account, place your linking code into your website and watch your account balance grow as your visitors become our customers. Vapor Fi also supplies a complete range of accessories including coils, tanks, batteries, and chargers. If you’re looking for CBD products, they can help you with that too. Note: Don’t forget to check out our blog post on CBD affiliate programs.

[index] [15317] [5303] [7383] [4811] [9553] [5285] [9504] [6286] [5225] [7530]